Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The rise of antibiotic resistance in many pathogens has been driven by the spread of a small number of strains, suggesting that some bacteria may be genetically pre-disposed to evolving resistance. Researchers at Oxford University have tested this hypothesis by quantifying differences in evolvability between pathogen strains and by searching for ‘potentiator’ genes that accelerate the evolution of resistance. Their results are published today in Nature Communications.

Bacterial colonies growing on agar plates © Andrei Papkou

Scientists from the Department of Zoology, Oxford University, show that a single gene that codes for an efflux pump predisposes some strains of pathogenic S.aureus to evolve high levels of ciprofloxacin resistance. Bacterial efflux pumps actively pump out chemicals from bacterial cells – sort of like a bacterial bucket brigade – and this an important way that bacteria cope with exposure to a range of toxic chemicals, including antibiotics.

Their experiments involved a common human pathogen, Staphylococcus aureus, that is an important source of antibiotic resistant infections in health care settings (ie MRSA). They used a broad-spectrum antibiotic called ciprofloxacin that was developed in the 1980s, and initially heralded as a solution to MRSA infections.

The full article is available on the University of Oxford website

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.